EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias wird Nachfolger von Andreas Reisse als CEO
|
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Schlagwort(e): Personalie Der Aufsichtsrat der SCHOTT Pharma Management AG hat heute Dr. Christian Mias mit Wirkung zum 1. Mai 2026 zum neuen Chief Executive Officer (CEO) von SCHOTT Pharma bestellt. Er folgt auf Andreas Reisse, der planmäßig Ende April 2026 in den Ruhestand gehen wird. Dr. Christian Mias ist seit 2007 in verschiedenen Führungspositionen innerhalb der SCHOTT Gruppe tätig, zuletzt als Leiter der Business Unit Electronic Packaging.
Ende der Insiderinformation
05.11.2025 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
| Sprache: | Deutsch |
| Unternehmen: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Deutschland | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indizes: | SDAX |
| Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2224602 |
| Ende der Mitteilung | EQS News-Service |
|
|
2224602 05.11.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 584,23 | 648,67 | 821,14 | 898,60 | 957,09 | 986,20 | |
| EBITDA1,2 | 0,00 | 131,94 | 164,10 | 219,73 | 239,00 | 257,55 | 280,30 | |
| EBITDA-Margin3 | 0,00 | 22,58 | 25,30 | 26,76 | 26,60 | 26,91 | 28,42 | |
| EBIT1,4 | 0,00 | 98,22 | 127,66 | 164,38 | 192,38 | 192,58 | 212,00 | |
| EBIT-Margin5 | 0,00 | 16,81 | 19,68 | 20,02 | 21,41 | 20,12 | 21,50 | |
| Net Profit (Loss)1 | 0,00 | 77,63 | 101,17 | 125,85 | 151,93 | 150,35 | 163,00 | |
| Net-Margin6 | 0,00 | 13,29 | 15,60 | 15,33 | 16,91 | 15,71 | 16,53 | |
| Cashflow1,7 | 0,00 | 104,40 | 132,21 | 182,12 | 181,65 | 225,33 | 207,00 | |
| Earnings per share8 | 0,00 | 0,51 | 0,67 | 0,83 | 1,01 | 0,99 | 1,08 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,12 | 0,15 | 0,18 | 0,23 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Ernst & Young
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Schott Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3ENQ5 | DE000A3ENQ51 | AG & Co. KGaA | 2.783,36 Mio € | 28.09.2023 | 9F2C268V+9J | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 18,30 | 25,26 | 0,72 | 21,79 | 3,63 | 12,35 | 2,91 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,15 | 0,18 | 0,23 | 1,24% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 04.02.2025 | 11.02.2026 | 13.05.2026 | 12.08.2025 | 11.12.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,22% | -21,47% | -26,55% | -33,91% | -31,56% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
